In our view the active management of convertibles is best achieved by a dedicated, specialist team that has the experience to exploit the many inefficiencies that are inherent in the market. The team adopts both a top-down and fundamentally driven, bottom-up approach with the flexibility to invest across a global opportunity set to help capture these inefficiencies and pricing anomalies.
As a liquid alternative, our convertibles-based strategies can have numerous advantages when included in a balanced portfolio.
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency and exchange rates. Investors may not get back the original amount invested.
Global convertibles strategies
Aviva Investors Global Convertibles Strategy
An actively managed, long-only strategy that aims to capture the asymmetric return profile of balanced convertible bonds.
Aviva Investors Global Convertibles Absolute Return Strategy
A market-neutral strategy targeting steady returns with low volatility in all market conditions.
Read more about the funds
- PDF 239.8 KB 3 pages
Aviva Investors - Global Convertibles Absolute Return Fund - Fund in Brief
- PDF 133.9 KB 2 pages
Aviva Investors - Global Convertibles Fund - Fund in Brief
- PDF 39.2 KB 1 page
An Introduction to Convertibles
- PDF 1.6 MB 17 pages
The case for actively managing convertible bond portfolios
- PDF 1.5 MB 17 pages
Convertible bonds in an absolute return context
Explore our fixed income range
Emerging market debt
A range of emerging market debt strategies that invest across hard and local currency markets.
Investment grade credit
A range of strategies that utilise portfolio construction to deliver attractive returns throughout the credit cycle.
A range of strategies that aim to capture the full potential of high yield bond markets while protecting to the downside.
A strategy that aims to enhance returns on cash by investing in short-maturity, highly rated fixed-income securities where T+0 liquidity is deemed unnecessary.
Fixed income views
What does the data say? Are we close to 1970’s-style stagflation?
29 Jul 2022
In this month’s instalment of our visual series on topical themes, we look at whether the global economy is heading towards stagflation.
Convertible bonds: Five questions with David Clott
19 Jul 2022
In the first of a new series, David Clott assesses the key recent developments in the convertible bond market and outlines why this could be an attractive entry point into the asset class with Rico Pedrett.
Bumpy ride set to continue for credit investors
18 Jul 2022
The co-managers of the Aviva Investors Strategic Bond strategy give their views on the outlook for credit markets following the worst first-half in at least 40 years.
The AIQ Podcast: Taking stock of nature risk
15 Jul 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
EMD: On the bread line
6 Jul 2022
Russia’s war in Ukraine has contributed to soaring food prices, supercharging global inflation. Poorer countries will likely be hardest hit, adding to the risk of social unrest. With public finances and incomes already under strain, emerging-market debt investors should be on high alert.
Inflation, volatility and default risk: The outlook for high yield
13 Jun 2022
The co-heads of our global high yield team explain how the asset class is standing up to current headwinds.
Conflict, commodities and China: The outlook for EMD
13 May 2022
Aaron Grehan and Nafez Zouk from our emerging market debt team explain how the asset class is standing up to some significant headwinds.
Game over for Zambia? A test case for debt restructuring
12 Apr 2022
The economic fallout from the pandemic has left several poorer nations struggling to repay debt. China, the biggest single creditor to many, could carry considerable clout in negotiations. Zambia will prove an early test case, argues Carmen Altenkirch.
What does the data say? Credit in focus
31 Mar 2022
In this month’s instalment of our visual series on topical themes, we look at key trends in the credit market.
Now for the hard part…..The challenge of delivering net zero
29 Mar 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
No time for heroes: How portfolio construction can help investors navigate unfamiliar economic and market regimes
22 Mar 2022
We are back in an old, but unfamiliar market regime. In a period where simple playbooks may falter, Jeremy Albers sets out why portfolio construction can make the difference.
Russia-Ukraine update: The ten key questions for EMD investors
18 Mar 2022
We assess the near and longer-term implications of Russia’s invasion of Ukraine on emerging-market debt.
How bond investors can influence companies and governments to change their behaviour for the better
17 Mar 2022
Bondholders are starting to use their power to influence corporate behaviour in areas such as climate change, social inequality and biodiversity loss.
China, inflation and politics: Three reasons for EM turbulence
24 Feb 2022
Emerging market assets have underperformed developed market peers over the past decade. While this has led to valuation gaps, selectivity will be critical, argues David Nowakowski.
Untapped potential: Harnessing the full power of bondholder engagement
31 Jan 2022
Investor influence has long been confined to that of equity shareholders. Yet bondholders wield a lot of power. Can they harness it for positive change?
The future of pharma: Increased returns or the age of biotech?
8 Dec 2021
After decades of low returns on research and development (R&D), the healthcare sector is producing a slew of innovations, from drugs to diagnostics. But with many coming from new entrants, will big pharmaceutical companies manage to keep up with the times?